AKT1 and neoplasm: These findings clearly indicate that the AS/BJO-NEs not only inhibit glycolytic metabolism, proliferation, invasion, and metastasis of OSCC by downregulating the AURKA-mediated PI3K/AKT/HIF-1α pathway, but may also exert anti-inflammatory and antioxidant effects through multiple targets and pathways to suppress tumor progression.